Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Harper Hubbeling"'
Autor:
Harper Hubbeling, Noura Choudhury, Jessica Flynn, Zhigang Zhang, Christina Falcon, Valerie W. Rusch, Bernard J. Park, Etay Ziv, Narek Shaverdian, Daphna Y. Gelblum, Annemarie F. Shepherd, Charles B. Simone, Abraham J. Wu, Daniel R. Gomez, Alexander Drilon, Andreas Rimner
Publikováno v:
JCO Precision Oncology.
PURPOSE Local therapy prolongs progression-free survival in patients with oligometastatic non–small-cell lung cancers treated with chemotherapy. We previously reported that local therapy also prolongs survival and time to next therapy in patients o
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
William A. Mehan, Justin F. Gainor, Alice T. Shaw, Kevin S. Oh, Beow Y. Yeap, Helen A. Shih, Emily Schapira, Harper Hubbeling
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 101:624-629
Purpose Despite the emerging role of programmed cell death-1 (PD-1) pathway inhibitors for patients with advanced lung cancer, a paucity of data are available on the activity of these agents among patients with brain metastases. We investigated the o
Autor:
Justin F. Gainor, William A. Mehan, Emily Schapira, Alice T. Shaw, Jessica J. Lin, Kelly Goodwin, Nora Horick, Kevin S. Oh, Helen A. Shih, Harper Hubbeling
Publikováno v:
Journal of Thoracic Oncology. 13:550-558
Introduction Intracranial metastases are a common cause of morbidity and mortality in patients with advanced NSCLC, and are frequently managed with radiation therapy (RT). The safety of cranial RT in the setting of treatment with immune checkpoint in
Autor:
Ibiayi, Dagogo-Jack, Marguerite, Rooney, Jessica J, Lin, Rebecca J, Nagy, Beow Y, Yeap, Harper, Hubbeling, Emily, Chin, Jennifer, Ackil, Anna F, Farago, Aaron N, Hata, Jochen K, Lennerz, Justin F, Gainor, Richard B, Lanman, Alice T, Shaw
Publikováno v:
Clin Cancer Res
BACKGROUND: Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is often driven by secondary ALK mutations. Here we investigated utility of plasma genotyping for identifying ALK resistance mutations at relapse on next-generat
Autor:
Andrzej Niemierko, Justin F. Gainor, William L. Hwang, Emily Schapira, Katie L. Hwang, Florence K. Keane, Harper Hubbeling
Publikováno v:
JAMA oncology. 4(2)
This cohort study evaluates the clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy.